[Health related quality of life among HIV-HCV co-infected patients].
BACKGROUND
To assess factors associated with higher levels of health-related quality-of-life among HIV-HCV co-infected injecting drug users and more specifically, to explore the role of injecting drug status and drug maintenance treatment on health-related quality-of-life.


METHODS
The two hundred and forty participants were patients enrolled in the MANIF cohort of HIV-HCV patients infected through injecting drug use who completed a self-administered questionnaire that included a health-related quality-of-life evaluation at the 42 month follow-up. A self-administered questionnaire collected information about socio-demographic characteristics, health-related quality-of-life (as measured by SF-12), injecting drug status and drug maintenance treatment, depressive symptoms, self-reported symptoms related to HIV treatment; clinical characteristics were obtained from medical records.


RESULTS
Higher levels of both mental and physical health-related quality-of-life were found in patients with no depressive symptoms, abstinent from drugs and experiencing few drug related problems. Patients on drug maintenance treatment who stopped injecting drugs had better mental health-related quality-of-life than injectors but lower levels of mental health-related quality-of-life than abstinent patients. Mental health-related quality-of-life was also independently higher in patients receiving high social support. Physical health-related quality-of-life was independently higher for patients who stopped injection, whether on drug maintenance treatment or not, for patients on anti-retroviral treatment and for patients who remained in clinical stage A.


CONCLUSIONS
Drug maintenance treatment seems to be associated with higher health-related quality-of-life among patients HIV-HCV co-infected by drug use, but it is still necessary to help patients cope with the mental impact of drug cessation. These results underline the need to provide regular psychological support and counselling for HIV-HCV co-infected injecting drug users during the medical follow-up for HIV-disease.
Préau
M
M
INSERM U379/ORS-PACA, Marseille. preau@marseille.inserm.fr
Protopopescu
C
C
Spire
B
B
Dellamonica
P
P
Poizot-Martin
I
I
Villes
V
V
Carrieri
M P
MP
D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use; D015331:Cohort Studies; D003376:Counseling; D003627:Data Interpretation, Statistical; D003863:Depression / Q000175:diagnosis / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D006679:HIV Seropositivity / Q000150:complications / Q000523:psychology; D015497:HIV-1; D006526:Hepatitis C / Q000150:complications* / Q000523:psychology; D006801:Humans; D008297:Male; D008691:Methadone / Q000008:administration & dosage / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D009294:Narcotics / Q000008:administration & dosage / Q000627:therapeutic use; D011788:Quality of Life / Q000523:psychology; D012944:Social Support; D012959:Socioeconomic Factors; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D011795:Surveys and Questionnaires; D013997:Time Factors
D044966:Anti-Retroviral Agents; D009292:Narcotic Antagonists; D009294:Narcotics; D002047:Buprenorphine; D008691:Methadone